代谢酶基因GSTM1和广西人群胃癌遗传易感性的关系

目的探讨代谢酶基因GSTM1多态性与广西地区人群胃癌遗传易感性之间的相关性。方法采用PCR技术检测广西地区121例胃癌患者和138例健康人的GSTM1基因多态性的分布频率,分析其与广西地区胃癌遗传易感性之间的相关性以及与吸烟、饮酒在胃癌易感性中的交互作用。结果胃癌组GSTM1（-）基因型频率（54．5％）显著高于对照组（39．1％）（X^2=6．140,P=0．013）。携带GSTM1（-）基因型的个体患胃癌的风险是携带GSTM1（＋）基因型个体的2．13倍（95％CI=1．079-1．831,P=0．013）。在吸烟者中,携带GSTM1（-）基因型的个体较携带GSTM1（＋）基因型的个体患胃癌的风险明显增加（OR=3．247,95％CI=1．067—2．328,P=0．015）。其增加程度远远高于总的胃癌风险（OR=2．129）。在饮酒者中,携带GSTM1（-）基因型的个体较携带GSTM1（＋）基因型的个体患胃癌的风险亦明显增加（OR=3．117,95％CI=1．020—2．863,P=0．033）。其增加程度远远高于总的胃癌风险（OR=2．129）。结论GSTM1（-）基因型显著增加广西地区人群患胃癌的风险,且显著增加吸烟、饮酒者患胃癌的风险。     

CYP2E1,GSTM1基因多态性与甘肃地区食管癌易感性

目的探讨细胞色素氧化酶P450,GSTM1的基因多态性与甘肃地区食管癌遗传易感性之间的以及基因—基因的交互作用。方法运用病例对照分子流行病学研究方法和聚合酶链反应方法对食管癌病例组和正常对照组基因DNA进行CYP2E1,GSTM1基因分型。结果CYP2E1基因pst1多态性的三种基因型在食管癌组和对照组的频率差异有统计学意义（χ2=12.59,P〈0.05）。携带C1/C1基因型个体发生食管癌的风险是携带其他基因型2.80倍（OR=2.80,95%C I=1.21-6.46）。食管癌组GSTM1（-）基因型频率显著高于对照组（χ2=10.292,P〈0.05）,携带GSTM1（-）的个体患食管癌的危险性显著高于GSTM1（＋）基因型的个体（OR=2.337,95%C I=1.39-3.93）。联合分析CYP2E1基因pst1多态性和GSTM1基因多态性,携带有C1/C1和GSTM1（-）基因型的个体患食管癌的风险高于携带GSTM1（＋）和C1/C2或C2/C2基因型的个体（OR=3.00,95%C I=1.7375-5.182）。结论CYP2E1,GSTM1基因多态性与食管癌易感性有关联,CYP2E1基因C1/C1基因型是食管癌的易感性基因,而GSTM1基因缺失使食管癌危险性增加,CYP2E1,GSTM1存在交互作用。     

中国汉族人群谷胱甘肽硫转移酶M1及T1基因多态性与先天性心脏病发病风险的关系

目的探讨中国汉族人群谷胱甘肽硫转移酶(glutathione S-transferases,GST)M1及T1基因(GSTM1/GSTT1)多态性与先天性心脏病(先心病)发病风险的关系。方法采用病例-对照研究(病例组365例,对照组372例),运用多重聚合酶链反应检测先心病患者及健康对照GSTM1/GSTT1基因型;并利用多因素非条件logistic回归模型,进行先心病发病风险影响因素关联强度及交互作用分析。结果 GSTM1/GSTT1基因多态性及研究对象母亲围孕期吸烟、饮酒、化学物质接触、孕前体质量指数、教育程度、定期产检以及怀孕知情时间在病例组和对照组之间分布存在明显差异(P<0.05)。GSTM1/GSTT1基因缺失与先心病发病风险显著正相关(OR=1.56,P=0.049;OR=1.73,P=0.036)。经logistic回归分析,GSTM1(-)/GSTT1(-)基因型和研究对象母亲围孕期吸烟、饮酒、化学物质接触以及孕前高体质量指数是先心病发病的高危因素,研究对象母亲围孕期定期产检以及摄入充足的叶酸是先心病的保护因素。研究对象母亲围孕期吸烟与GSTM1(-)/GSTT1(-)基因型之间具有正相加交互作用,与母亲围孕期不吸烟且GSTM1/T1基因未缺失的研究对象相比,其母亲围孕期吸烟且携带GSTM1(-)和(或)GSTT1(-)基因型的先心病发病风险显著上升(OR=9.01,3.87,3.01;95%CI:1.73～39.69,1.21～19.57,1.13～9.69)。结论 GSTM1/GSTT1基因缺失是先心病发病风险的独立危险因素;GSTM1(-)/GSTT1(-)基因型与孕母围孕期吸烟在先心病的发生中具有协同作用。     

N-乙酰基转移酶2及谷胱甘肽S转移酶M1基因多态性与抗结核药物性肝损伤的关系研究

目的 研究药物代谢酶NAT2、GSTM1、GSTT1的基因多态性与抗结核药物肝损伤的关系,阐明抗结核药物性肝损伤（antituberculosis drug induced liver injury,ATDILI）的分子机制.方法 解放军第三○九医院结核科2008-2009年度住院初治结核病患者208例,具有明确抗结核药物性肝损伤发生的患者为肝损伤组（共101例）,无抗结核药物性肝损伤发生的患者为对照组（共107例）,通过PCR扩增产物直接测序的方法分析两组的NA T2基因多态性并分型.通过多重PCR方法检测两组患者GSTM1、GSTT1是否存在基因型缺失.以SPSS12.0软件进行x2检验处理,比较两组之间各基因型分布频率的差异,并计算各基因型风险系数（odds ratio,OR值）及95％可信区间（95％ CI）,分析疾病与基因的关联强度.结果 （1）肝损伤组患者中,39.6％ （40/101）为NAT2慢乙酰化基因型;对照组中,12.2％（13/107）为NA T2慢乙酰化基因型.NA T2慢乙酰化基因型者发生抗结核药物性肝损伤的风险系数（OR值）为4.74（95％CI＝2.42～9.28;x2 =20.62,P＜0.05）.（2）肝损伤组中,GSTM1缺失基因型占63.4％（64/101）,对照组GSTM1缺失基因型占51.4％（55/107）;两组比较GSTM1缺失基因型发生药物性肝损伤的OR值偏高（但无统计学意义）,为1.64（95％CI＝0.94～2.84,x2＝3.038,P＞0.05）.肝损伤组中,GSTT1缺失基因型占47.5％（48/101）,对照组GSTT1缺失基因型占45.8％（49/107）,两组比较OR值接近,为1.07（95％CI＝0.62～1.85,x2＝0.063,P＞0.05）.（3）肝损伤组中同时具有NA T2慢乙酰化基因型及GSTM1缺失基因型的患者29例,对照组5例,发生抗结核药物性肝损伤的风险系数OR值高达10.21（95％CI＝3.87～26.96,x2＝20.62,P＜0.005）.结论 NAT2基因的慢乙酰化基因型及GSTM1缺失基因型可能与ATDILT有关.     

谷胱甘肽S-转移酶M1、T1基因多态性与骨肉瘤易感性的Meta分析

目的 定量分析谷胱甘肽S-转移酶M1、T1(GSTM1、GSTT1)基因多态性与骨肉瘤易感性的关系.方法 检索PubMed、Embase、CNKI、维普、万方数据平台从建库到2013年2月的文献,对符合本实验纳入标准和排除标准的随机对照临床研究,运用RevMan5.0.0软件进行Meta分析.结果 共纳入3篇文献,累计样本量为914例,其中病例组202例,对照组712例.Meta分析见GSTTI位点的多态性与骨肉瘤易感性有显著关联,而GSTM1和骨肉瘤无显著关联(基因型GSTM1空白对GSTM1非空白:OR=1.21,95％ CI:0.86～1.70,P=0.27;基因型GSTT1空白对GSTT1非空白:OR=1.58,95％ CI:1.11 ～2.25,P=0.01).结论 GSTT1基因多态性与骨肉瘤相关,GSTT1空白基因型可能增加骨肉瘤的发病.     

细胞色素P4501A1、谷胱甘肽转硫酶基因多态性与儿童急性淋巴细胞白血病的相关性研究

目的探讨生物代谢酶细胞色素P4501A1、谷胱甘肽转硫酶M1、T1基因多态性与儿童急性淋巴细胞白血病(ALL)的相关性。方法采用病例对照研究方法,应用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)技术对89例儿童ALL患儿以及90名健康对照者的CYP1A1 Msp Ⅰ多态(T264C)、GSTMI和GSTT1等基因的多态分布进行分析。结果儿童ALL组的CYP1A1基因Msp Ⅰ多态纯合子突变型(C型)的频率与对照组差异有统计学意义(P0.05),携带纯合子突变型的儿童患ALL的危险度比杂合子突变型(B型)与野生型(A型)儿童的高(OR=1.997,95% CI:1.024～3.896)。GSTM1缺失型分布频率与对照组相比差异有统计学意义(P0.05,OR=2.709,95%CI:1.427～5.146),GSTT1缺失型分布频率与对照组相比差异无统计学意义(P0.05)。同时携带CYPlAl C型、GSTM1、GSTT1缺失型的联合基因型儿童患ALL的风险增加(OR=2.235,95% CI:1.111～4.497)。结论 CYP1A1基因Msp Ⅰ多态纯合子突变型(C型)、GSTM1缺失型与儿童ALL的易感性可能相关,GSTT1缺失型与儿童ALL易感性可能不相关;同时携带CYP1A1 C型与GSTM1、GSTT1缺失基因型可能是儿童ALL发病的易感因素之一。     

DNA修复基因XRCC3多态性与肺癌易感性的关系

目的 研究DNA修复基因XRCC3多态性与肺癌易感性的关系。方法采用病例一对照研究，于2006年9月至2007年1月收集上海肺科医院原发性肺癌患者291例及同期住院的非肿瘤患者273例，应用Taqman探针结合实时荧光PCR方法分析病例组和对照组XRCC3基因Thr241Met的多态性分布，比较不同基因型与肺癌易感性的关系以及基因多态性与吸烟对肺癌的交互作用。对照组与病例组的比较用X。检验，以调整比值比及95％可信区间表示相对危险度，所有统计检验均为双侧概率检验，所有资料均用SPSS软件进行统计。结果与携带XRCC3密码子241野生纯合基因型（Thr／Thr）且不吸烟者相比，携带同样基因型且吸烟者患肺癌的风险会增加，其调整比值比（OR值）为2．47[95％可信区间（CI）为1．49-4，08，P〈0．01]；携带有杂合基因型（Thr／Met）且吸烟者患肺癌的风险也会增加，其调整OR值为2．28（95％CI为1．21-6．60，P=0，017）。野生纯合基因型（Thr／Thr）且吸烟量少于30包年可能对肺腺癌有较弱的保护作用（OR=0．49，95％CI为0．26-0．93，P=0，03）。携带有XRCC3密码子241Met等位基因且吸烟者患肺鳞癌的风险明显增加（调整OR=9．69，95％CI为3．27-28．72，P〈0．01）。携带241Met等位基因且吸烟剂量〈30包年和≥30包年的患者患肺鳞癌的风险也不同，OR值分别为8，00（95％CI为1．97-32．52，P〈0．01）和11．67（95％CI为2．98～45．73，P〈0．01）。结论DNA修复基因XRCC3多态性可能对肺癌易感性产生影响，并可能与吸烟有一定的协同作用。     

GSTM1基因多态性与肺癌发病的相关性研究

目的探讨谷胱甘肽硫转移酶M1（GSTM1）基因多态性与肺癌易感性的关系，以期用于肺癌的筛检。方法用PCR法分析56例肺癌（简称肺癌组）和42例健康对照组GSTM1基因型，并用Logistic多因素回归法分析可能影响GSTM1的职业环境因素、生活习惯、及宿主个体因素。结果肺癌组GsTM1基因缺失型[GSTM1（-）]发生率达71．43％，显著高于对照组的45．24％，差异有统计学意义，P〈0．05；GSTM1（-）型与肺癌呈高度联系强度，OR=3．09（95％CI=1．32～6．94）；Logistic回归分析表明，职业接触PAHs（OR=6．6939，P=0．009）、吸烟（OR=9．7058，P=0．0010）、既往肺病史（OR=7．5233，P=0．0465）与GST M1（-）型相关。结论GST M1（-）型个体增加了肺癌发生的风险性，可作为宿主肺癌易感性的遗传标志。     

ABCA1基因多态性与冠心病易感性的关联研究

目的探讨三磷酸腺苷结合盒转运子A1（ATP binding cassette transporter1,ABCA1）基因R219K及M883I单核苷酸多态性（SNP）位点与脂代谢和冠心病（coronary heart disease,CHD）易感性的关系。方法以医院为基础的病例-对照研究。经冠状动脉造影确诊的冠心病病例224例,同一地区正常对照248例。分别以PCR-RFLP和PIRA-PCR对ABCA1第219密码子G→A（Arg219Lys）和第883G→A（Met883Ile）密码子多态进行检测,比较不同基因型与个体血脂水平和冠心病患病风险的关系。结果吸烟、高血压和高血糖是冠心病的独立危险因素。与携带219RR基因型者比较,携带至少1个219K等位基因者（即RK和KK基因型）冠心病患病风险显著降低59％（OR = 0．41,95％ CI = 0．27～0．61）。而在883位点,II基因型携带者患冠心病率较低（OR = 0．54,95％ CI = 0．26～1．11）。而两位点联合作用分析发现与携带219RR,883MM或883MI基因型者相比较,携带其他组合基因型的个体冠心病患病风险降低61％（OR = 0．39,95％ CI = 0．26～0．60）。另外,对照组中携带219K等位基因者血清HDL-C水平显著高于219K非携带者（P = 0．037）,提示Arg219Lys位点的多态改变主要通过改变HDL-C水平影响个体冠心病的患病风险。结论ABCA1 R219K可能与中国汉族人群冠心病遗传易感性有关,血清高密度脂蛋白可能是其作用靶点。     

核苷酸切除修复基因ERCC1、XPD和XPC多态性与燃煤污染型地方性砷中毒的关系研究

目的 探讨核苷酸切除修复基因ERCCI、XPD、XPC不同基因型与燃煤污染型砷中毒发病风险的关系.方法 以贵州省兴仁县交乐村燃煤污染型砷中毒病区229例砷中毒患者作为病例组,以有相似生活习惯、无燃用高砷煤史的非砷暴露村大果朵村198名居民作为对照组,每人抽取外周静脉血约2 ml提取DNA,采用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)技术进行ERCC1 C8092A 、XPD Lys751 Gln、XPD Asp312Asn、XPD Arg156Arg、XPC P(AT+/-)多态位点检测.结果 病例组ERCC1 C8092A位点CA/AA基因型分布频率[ CA:29.78％ (67/225)、AA:10.67％ (24/225)]显著高于对照组[CA:23.08％( 45/195)、AA:5.13％ (10/195),x2=8.116,P＜0.05];其余各基因多态位点的基因型分布频率差异无统计学意义(x2值分别为5.649、4.394、0.865、1.490,P均＞0.05).携带ERCCI 8092CA+ AA、XPD Lys751Gln+ Gln751Gln 、XPD Asp312Asn+ Asn312Asn基因型个体分别较携带ERCC1 8092CC、XPD Lys751Lys、XPD Asp312Asp基因型个体发生砷中毒的风险升高1.780、1.681、1.790倍(95％CI分别为1.174～2.698、1.081～2.615和1.014～3.158,P均＜0.05);单一的XPD 基因Arg156Arg位点、XPC基因P(AT+/-)位点对砷中毒的发病风险没有影响(P均＞0.05).结论 核苷酸切除修复基因ERCC1 C8092A、XPD Lys751 Gln和Asp312Asn位点的多态性与燃煤污染型砷中毒的发病风险有关.     

Combined GSTM1 and GSTT1 null genotypes are associated with a lower risk of papillary thyroid cancer

Individual susceptibility to cancer is influenced by polymorphisms of genes encoding drug-metabolizing enzymes such as the glutathione S-transferases (GST). The null polymorphisms of the GSTM1 and GSTT1 genes have been associated to a modified risk of several cancers but studies of thyroid cancer have produced conflicting results. The aim of this study was to investigate the relationship between these polymorphisms and the risk of papillary thyroid cancer (PTC). A total of 188 patients with PTC and 247 controls were genotyped using a PCR-based assay. Odds ratios (OR) and 95% confidence intervals (CI) for each homozygous null genotype were determined. The frequency of each of the GSTM1 and GSTT1 null genotypes did not differ significantly between patients and controls (OR=0.83, 95%CI: 0.56-1.21; p=0.328; and OR=0.66, 95%CI: 0.39-1.12; p=0.123, respectively), but the frequency of individuals that had the combined GSTM1 null/GSTT1 null genotypes was significantly lower in the patient group (OR=0.50, 95%CI: 0.26-0.97; p=0.040). The GSTM1 null genotype was associated with a lower risk of advanced cancer stages (III/IV) (OR=0.50, 95%CI: 0.26-0.96; p=0.036) and the GSTT1 null genotype was associated with a lower risk of the follicular variant of PTC (OR=0.31, 95%CI: 0.10-0.97; p=0.044). These results suggest that GSTM1 and GSTT1 null genotypes are weak, yet possible, modifiers of the risk of PTC. This protective effect may be due to a role of the GSTM1 and GSTT1 encoded enzymes in the metabolic activation of putative thyroid carcinogens or in other pathways involved in thyroid carcinogenesis.     

Genetic polymorphism at GSTM1 and GSTT1 gene loci and susceptibility to oral cancer

GSTs are phase II enzymes which are involved in the detoxification of active metabolites of many potential carcinogens from tobacco smoke and therefore may play an important role in modulating susceptibility to tobacco related cancers. This study evaluates the influence of genetic polymorphisms of GSTM1 and GSTT1 gene loci on susceptibility to oral cancer. The genotyping was based on multiplex PCR assay that identified the GSTM1 and GSTT1 null (-/-) genotypes but didn't distinguish homozygous wild type+/+ and heterozygous +/- individuals. Genomic DNA was isolated from cases with oral cancer (n=40) and normal controls (n=87). The prevalence of the GSTM1 null genotypes was 29/87 (33.3%) and 21/40 (52.5%) in controls and oral cancer cases, respectively but the differences were not significant (OR=2.2; 95%CI=0.96-5.1; p=0.06). The frequency of homozygous GSTT1 null genotype in cancer cases was 17/40 (42.5%) as compared to 13/87 (14.94%) in controls and the differences were highly significant (OR=4.2; 95%CI=1.64-10.9; p=0.0002). Oral cancer cases had higher proportion of both GSTM1 and GSTT1 null genotypes as compared to controls but the differences were not statistically significant (OR=2.9; 95%CI=0.71-11.9; p=0.17). When individuals were categorized into two groups, no differences were observed for GSTM1 null genotype frequencies in control and cancer cases (OR=2.9; 95%CI=0.9-9.6; p=0.08) (OR=1.6; 95%CI=0.44-6.1; p=0.58) in <=50 yrs and >50 yrs of age groups. Significant differences between control and cancer cases were observed for GSTT1 null genotypes both in <=50 yrs and >50 yrs of age groups (OR=4.0; 95%CI=1.1-15.0; p=0.03) (OR=4.5; 95%CI=0.97-22.29; p=0.05), respectively. The effect of smoking on GSTM1 null individuals was not found significant (OR=1.0; 95%CI=0.19-4.86; p=0.75) but it was significant in case of GSTT1 null individuals (OR=6.33; 95%CI=1.0-44.1; p=0.02). Our results thus suggest that GSTT1 gene polymorphisms modulate susceptibility to tobacco-related cancer of the oral cavity.     

Polymorphisms of the glutathione S-transferases mu-1 (GSTM1) and theta-1 (GSTT1) and the risk of advanced alcoholic liver disease

OBJECTIVE: The aim of this study was to determine whether null genotypes for glutathione transferase mu-1 (GSTM1) and theta-1 (GSTT1) influence the risk of development of advanced alcoholic liver disease. MATERIAL AND METHODS: GSTM1 and GSTT1 genotypes were identified on DNA through multiple analysis with polymerase chain reaction in 153 subjects diagnosed with advanced alcoholic liver disease and in 241 healthy controls. RESULTS: The frequency of the GSTM1 null genotype was not different between patients and controls (36.6% versus 41.1%, non-significant). The GSTT1 null genotype was more frequently found in patients than in controls (32% versus 22%, odds ratio 1.67, 95% CI 1.03-2.71, p =0.027). Moreover, patients were more likely to be simultaneous carriers of both GSTM1 and GSTT1 null genotypes (odds ratio 4.30, 95% CI 1.89-9.97, p =0.0003). CONCLUSIONS: The GSTT1 null genotype is more frequent among patients with advanced alcoholic liver disease than in controls. The coincidence of this genotype with the GSTM1 null genotype is four times more likely in patients. We suggest that polymorphisms affecting the activity of the glutathione S-transferase isoforms M1 and T1 may be associated with the risk of developing chronic severe ethanol liver damage.     

Increased risk for acute myeloid leukaemia in individuals with glutathione S-transferase mu 1 (GSTM1) and theta 1 (GSTT1) gene defects

OBJECTIVES: Glutathione S-transferases (GST) modulate the effects of exposure to various cytotoxic and genotoxic agents, including those associated with increased risks of the myelodysplastic syndrome (MDS), acute myeloid leukaemia (AML) and aplastic anemia (AA). Both the GST mu 1 (GSTM1) and GST theta 1 (GSTT1) genes have a null variant allele in which the entire gene is absent. In this study, we tested whether null genotypes for the GSTM1 and GSTT1 genes altered the risks for MDS, AML and AA. METHODS: Genomic DNA from 49 MDS, 38 AML and 37 AA patients and 276 controls was analysed using the polymerase chain reaction (PCR). RESULTS: The frequencies of GSTM1 (73.6%) and GSTT1 (34.2%) null genotypes were significantly higher in AML patients than in the controls (36.9 and 18.1%, respectively). A higher frequency of the combined null genotype for both genes was also observed in patients with AML (26.3% compared with 5.0% in the controls). In contrast, no differences in the frequencies of the null genotypes were found among MDS patients, AA patients and the controls. CONCLUSION: Our observation of a 4.7-fold (95% CI: 2.1-11.0) and 2.3-fold (95% CI: 1.0-5.2) increased risk associated with the GSTM1 and GSTT1 null genotypes, respectively, and a 6.6-fold (95% CI: 2.4-7.9) increased risk associated with the combined null genotype presents preliminary evidence that the inherited absence of this carcinogen detoxification pathway may be an important determinant of AML.     

CYP1A1, GST gene polymorphisms and risk of chronic myeloid leukemia

PRINCIPLES: Associations between polymorphisms for genes encoding enzymes involved in biotransformation of xenobiotics and susceptibility to several cancers have been shown in several studies. The aim of the present study is to investigate the influence of cytochromes P450 (CYP450) 1A1*2C and Glutathione S-transferases (GSTs) (T1 and M1) gene polymorphisms in susceptibility to chronic myeloid leukaemia (CML). METHODS: The frequency of CYP1A1 Ile/Val alleles and of GSTT1 and GSTM1 homozygous deletions was examined in 107 patients with CML and 132 healthy controls by PCR and/or PCRRFLP methods using blood samples. RESULTS: The frequency of CYP1A1 Val allele was found to be 19.2% in CML patients and 4.4% for controls, indicating that persons carrying this allele had an increased risk of CML (OR = 5.10, 95% CI: 2.60-9.97). The frequency of individuals carrying the GSTT1 null genotype was higher among CML patients (40.2%) compared to controls (19.2%) (OR = 2.82, 95% CI: 1.58-5.05; p <0.001). Therefore, GSTT1 present genotype may be a protective factor for CML. Although GSTM1 null genotype frequency was slightly higher in the patient group (44.9%) than in the controls (42.3%), this difference was not statistically significant (OR = 1.11, 95% CI: 0.66-1.86; p = 0.693). Individuals with GSTM1 null genotypes without the T allele have a 5.981 higher risk for CML than those who have the T allele. CONCLUSIONS: This data suggests that polymorphic CYP1A1 and GSTT1 genes appear to affect susceptibility to CML.     

谷胱甘肽S-转移酶M1、T1基因多态与散发性大肠腺癌遗传易感性

目的　探讨谷胱甘肽S 转移酶 (GST)M1、T1基因多态与散发性大肠腺癌 (SCRAC)遗传易感性的关联。方法　应用多重聚合酶链反应 (PCR)技术 ,对经病理组织学确诊的 10 4例SCRAC患者及同期在本院体检的无血缘关系的 10 1例健康人 ,检测其GSTM1和GSTT1基因多态性。结果　 (1)在健康人和SCRAC患者 ,GSTM1、GSTT1空白基因型的频率差异均无显著性 (前者 4 6 5 % :5 6 7% ,χ2 =2 13,P >0 0 5 ;后者 4 7 5 % :6 0 6 % ,χ2 =3 5 2 ,P >0 0 5 )。 (2 )GSTM1空白基因型频率在近端与远端SCRAC患者间、在老年与非老年SCRAC间的频率差异均无显著性 ;而GSTT1空白基因型的频率差异有显著性 (前者 4 4 4 % :6 6 2 % ,χ2 =3 97,P <0 0 5 ;后者 70 9% :4 9 0 % ,χ2 =5 2 1,P <0 0 5 )。 (3)GSTM1、GSTT1均为空白基因联合型的个体患SCRAC的危险性升高 4 33倍 (9 6 % :2 6 9% ,χ2 =7 89,ν =3,P <0 0 5 )。结论　单独的GSTM1或GSTT1空白基因型与SCRAC遗传易感性无关 ,但GSTT1空白基因型与远端SCRAC遗传易感性有关 ,且多见于老年患者。GSTM1、GSTT1均为空白基因的联合基因型是SCRAC的易感基因型。     

Glutathione S-transferase M1 and T1 polymorphisms and cervical cancer risk: a meta-analysis

There were some studies on the associations between Glutathione S-transferase M1 (GSTM1) and Glutathione S-transferase T1 (GSTT1) polymorphisms and cervical cancer (CC) risk, but the results were inconsistent. Thus, a meta-analysis was performed. The electronic databases PubMed, Science Direct, CBM, and CNKI were searched for possible studies. Finally, 16 studies (1,627 cases and 2,161 controls) were included. For the GSTM1 and GSTT1 polymorphisms, the unadjusted odds ratios (OR) and 95% confidence intervals (95% CI) from each study were used to estimate summary OR. Subgroup analyses by ethnicity and histological type of CC were also performed. For the GSTM1 polymorphism, the null genotype of GSTM1 was associated with an increased CC risk in total population (OR=1.32, 95% CI=1.06-1.66). Similar association was found in Asians (OR=1.47, 95% CI=1.11-1.94), but not in Caucasians (OR=0.96, 95% CI=0.73-1.27). For the GSTT1 polymorphism, the null genotype of GSTT1 was not statistically significantly associated with CC risk in total population (OR=1.36, 95% CI=0.97-1.90). This result was also found in Asians (OR=1.27, 95% CI=0.87-1.85) and Caucasians (OR=1.09, 95% CI= 0.66-1.79), but not in Latinos (OR=4.58, 95% CI= 2.04-10.28). For the GSTM1/GSTT1 interaction analysis, the dual null genotypes of GSTM1/GSTT1 were significantly associated with increased CC risk in total population (OR=1.77, 95% CI= 1.14-2.75), and all the six studies were from Asia. For subgroup analyses by histological type of CC, the three aspects of the analyses above were all not significantly associated with CC risk in squamous cell carcinoma and adenocarcinoma, respectively. The null genotype of GSTM1 and the dual null genotypes of GSTM1/GSTT1 were risk factors in CC, and the null genotype of GSTT1 was not associated with CC risk.     

新疆哈萨克族人群谷胱甘肽S转移酶M1、T1基因多态性

目的 探讨谷胱甘肽S转移酶M1、T1基因多态性在新疆哈萨克族人群中分布的特点.方法通过多重聚合酶链反应对新疆哈萨克族264例个体 GSTM1、GSTT1基因型进行检测.结果 GSTM1、GSTT1基因缺失型在新疆哈萨克族人群中频率分别为47%及36.4%,同时为GSTM1、GSTT1基因缺失型的频率为20.5%.结论 新疆哈萨克族人群GSTM1、GSTT1基因多态性与汉族及其他少数民族存在一定差异.     

Polymorphisms at GSTM1 and GSTT1 gene loci and susceptibility to cervical cancer in Indian population

Multiple allelism at loci encoding detoxifying enzymes is associated with cancer risk. Glutathione S-transferase (GSTs) catalyzes the conjugation of glutathione to numerous potentially genotoxic compounds. This study evaluates the influence of genetic polymorphisms of GST M1 and GST T1 on susceptibility to cervical cancer. A multiplex polymerase chain reaction method was used to detect the presence or absence of the GSTM1 and GSTT1 genes in genomic DNA isolated from cases with cervical cancer (n=142) and normal controls (n=96). The results showed that the frequency of homozygous GSTM1 null genotype was higher in cervical cancer cases (57.0%) as compared to controls (34.4%) and the differences were significant (p<0.05), OR=2.5, 95% CI: 1.4--4.5. The frequency of homozygous GSTT1 null genotype in cancer cases was 19.7% in comparison to 12.5% in controls, however, the difference was not statistically significant (OR=1.7, 95% CI: 0.8-3.8). Significant difference was found between the cases and controls in the distribution of the null genotype of GST M1 in individuals aged above 45 years (p=0.04), but this difference was not significant in individuals aged below 45 years (p=0.06). No significant differences were found in cervical cancer cases and controls when data were analyzed according to age group for GSTT1 null genotype. Further, the combined analysis of both GSTM1 null and GSTT1 null genotypes did not appear to influence the susceptibility to cervical cancer, suggesting that polymorphisms of other detoxifying enzymes may play a significant role in cervical carcinogenesis.     

GSTT1, GSTM1 and GSTP1 polymorphisms and susceptibility to juvenile idiopathic arthritis

OBJECTIVE: In this study we have analyzed GSTM1, GSTT1 and GSTP1 polymorphisms in patients with juvenile idiopathic arthritis (JIA), to investigate a possible role of these genes as genetic components of the disease. METHODS: A total of 103 individuals (49 oligoarticular, 41 polyarticular and 13 systemic) were analyzed for the three polymorphisms, using a PCR/RFLP methodology. RESULTS: We have observed significantly increased frequencies of individuals with GSTT1 null genotype in JIA patients comparing to controls (37% x 21%; p=0.0183). There was a 2-fold increased risk (OR 2.2, 95% CI 1.2-4.1) associating the disease with the GSTT1 null genotype. Considering the subgroups (oligoarticular, polyarticular and systemic), the results indicated an association between polyarticular and systemic patients and the GSTT1 null genotype. There was a 2-fold increased risk for polyarticular patients (OR 2.4, 95%, CI 1.1-5.4), and a 4-fold increased risk for systemic patients (OR 4.4, 95%, 1.3-14.5). CONCLUSION: The GSTT1 null genotype seems to be involved in polyarticular and systemic JIA.